OTC Drugs, Dietary Supplements Merit Scant Mention In $7.2Bn FDA FY2024 Budget Request
Executive Summary
Supplements and OTC drug categories each mentioned once in FY2024 budget request for agency published by HHS. Broader document provided by White House OMB makes no mention of either category while emphasizing proposed increase for FDA’s food programs.
You may also be interested in...
US FDA Notes Concerns At Multiple Formula Plants After One Linked To Contamination, Shortage
Agency sends letters to manufacturers and other businesses involved in production and distribution “to assist industry in improving the microbiological safety of powdered infant formula.” Information from “routine surveillance inspections” of facilities and “for-cause inspections to follow up on consumer complaints” noted in letters.
‘Recipe For Disaster’ In Supplement Manufacturing? US DoJ Attorney Cooks Up Likely Causes
"You end up with a recipe for maybe there's adulterants in the product. Maybe the product wasn't manufactured according to the spec, so it's misbranded. Worse, there could be adulterants. In some of those ingredients, there's a lot of potential failures,” says Patrick Runkle, senior litigation counsel at DoJ Consumer Protection Branch, during FDL conference.
US FDA Supplement Facility Inspection Numbers Back To Typical Along With GMP Problems Found
Supplement facility GMP inspections by FDA in 2022 along with the frequency of form 483s sent to firms following inspections return to roughly pre-pandemic annual numbers after dipping during 2020 and 2021.